Clinical Trial: Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07917078) titled 'Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features' on Oct. 15.

Brief Summary: Alteplase, a recombinant tissue plasminogen activator (rt-PA), is commonly used for thrombolytic treatment in patients with high-risk acute pulmonary thromboembolism (PTE), whereas the role of thrombolysis in intermediate-risk PTE remains controversial. This multicenter, randomized controlled trial will compare the efficacy and safety of reduced-dose alteplase (25 mg administered intravenously over 2 hours) plus standard anticoagulation with standard anticoagulation alone in patients with intermediate-risk PTE who hav...